Urokinase-type plasminogen activator receptor: a beacon of malignancy?
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.
Drapkin
Ronny
R
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. ronny_drapkin@dfci.harvard.edu
Clauss
Adam
A
Skates
Steven
S
D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011506:Proteins / Q000032:analysis; D011956:Receptors, Cell Surface / Q000097:blood; D055293:Receptors, Urokinase Plasminogen Activator
D014408:Biomarkers, Tumor; C486327:Nbr1 protein, rat; C524898:PLAUR protein, human; C524900:Plaur protein, rat; D011506:Proteins; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator
Obstet Gynecol. 2007 Jun;109(6):1342-50
17540806
Med Res Rev. 2004 Jan;24(1):13-39
14595671
Mol Cell Proteomics. 2004 Apr;3(4):355-66
14764655
N Engl J Med. 1983 Oct 13;309(15):883-7
6310399
Histol Histopathol. 2008 Feb;23(2):227-36
17999379
Lancet. 1999 Apr 10;353(9160):1207-10
10217079
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
N Engl J Med. 2004 Dec 9;351(24):2519-29
15590954
Trends Biotechnol. 2007 Jan;25(1):33-9
17084931
Obstet Gynecol. 2006 Jan;107(1):77-85
16394043
J Clin Epidemiol. 2007 Dec;60(12):1205-19
17998073
Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S
11189683
Gynecol Oncol. 2008 Feb;108(2):402-8
18061248